Ask AI

Hitting the Target in Atopic Dermatitis: Interdisciplinary Team Training for Leveraging IL13 Inhibitors to Address the Burden of Disease

Gain in-depth knowledge on the role of IL-13 in atopic dermatitis pathophysiology, the current evidence on using IL-13 inhibitors in moderate to severe disease, and the strategies to employ in patient selection for these targeted therapies, through expert-written ClinicalThought commentaries, downloadable slides, and an on-demand webcast.

Share

Program Content

Activities

IL-13 Inhibition for Atopic Dermatitis
Addressing the Burden of Atopic Dermatitis: IL-13 Inhibition for Moderate to Severe Disease
Clinical Thought
Congratulations: You achieved a completion on 04/09/2022

Released: August 28, 2025

Expires: August 27, 2026

Provided by

ProCE Banner

Provided by Clinical Care Options, LLC, in partnership with Practicing Clinicians Exchange and Smart Patients.

Supporters

Supported by an educational grant from Lilly.

Lilly

Partners

Practicing Clinicians Exchange, LLC

ProCE Banner

Smart Patients

ProCE Banner